Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat + Trastuzumab Deruxtecan in HER2 Low/Ultra-low/Null Metastatic Breast Cancer
NCT05633979Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2023
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of valemetostat in breast cancer (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Objective Response Rate, Maximum Tolerated Dose and 1 more. Started Feb 2023; status: active, not recruiting.
02
Drugs
valemetostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05633979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05633979.